Mednax Inc

Most Recent

  • uploads///AdobeStock_

    Tesla Bear Jim Chanos Shorting Grubhub, DaVita

    On September 19, at Delivering Alpha Conference, Jim Chanos said Grubhub (GRUB) is a very good short. He said that Guruhub is almost not making any money.

    By Rabindra Samanta
  • uploads///medic _
    Company & Industry Overviews

    DaVita’s Valuation on September 17

    DaVita currently trades at a forward PE multiple of 15.2x compared to the industry average of 15.1x as of September 17.

    By Mike Benson
  • uploads///Jim Chanos Shorting Bets
    Fund Managers

    Will Jim Chanos’s Short Bet on Mednax and Envision Be Profitable?

    Mednax and Envision Healthcare’s (EVHC) stock price fell 1.45% and 1.72%, respectively, on Wednesday, July 18.

    By Sarah Sands
  • uploads///stethoscope _
    Company & Industry Overviews

    What Analysts Recommend for American Renal Associates Holdings

    American Renal Associate Holdings (ARA) is the largest dialysis services provider in the United States.

    By Kenneth Smith
  • uploads///Mednax Risks
    Company & Industry Overviews

    Key Risks Facing Mednax in 2017

    Mednax (MD) bills payors for services provided to patients. These payors consist of government programs like Medicare and Medicaid, contracted managed care, third parties, and private pay patients.

    By Kenneth Smith
  • uploads///mednax revenue growth
    Company & Industry Overviews

    Understanding Mednax’s Financial Position

    In 3Q17, hurricanes negatively affected Mednax’s (MD) revenues by close to $2 million. According to the company, acquisitions in radiology, anesthesia, and neonatology contributed around 430 basis points to revenue growth.

    By Kenneth Smith
  • uploads///Mednax Business Strategy
    Company & Industry Overviews

    A Closer Look at Mednax’s Business Strategy

    Mednax (MD) has a proven track record of expertise in the administration of physician services and a methodical approach to clinical data warehousing in fields such as research, education, and quality.

    By Kenneth Smith
  • uploads///Mednax Analysts Reco
    Company & Industry Overviews

    The Latest Wall Street Recommendations for Mednax

    Of the total 14 analysts covering Mednax (MD) in December 2017, three analysts have given the stock a “buy” or higher rating and ten have given it a “hold” rating while one analyst has given it a “sell” rating.

    By Kenneth Smith
  • uploads///US High Yield Bond Market Issuance
    Company & Industry Overviews

    High Yield Bond Issuance Fell in December on Rate Hike, Holidays

    Let’s look at the high yield bond markets. Junk bond issuers stayed away from the primary market for three successive weeks in December due to holidays.

    By Lynn Noah
  • uploads///Junk Bond Yields in  and
    Company & Industry Overviews

    Mednax Issued Most Junk Bonds Back in December 2015

    Mednax is a national medical group. It had issued junk bonds worth $750 million on December 1. Mednax would use the proceeds of the loan for refinancing.

    By Lynn Noah
  • uploads///Estimated Flows for High Yield Bond Funds
    Macroeconomic Analysis

    High-Yield Bond Fund Flows in 2015: Not a Pretty Picture

    High-yield bond funds have become out of favor with investors. Recently, the ICI released weekly data on estimated fund flows for high-yield bonds funds.

    By David Ashworth
  • uploads///US High Yield Bond Market Issuance
    Company & Industry Overviews

    Why Did High-Yield Bond Issuers Avoid the Primary Market?

    High-yield bond issuance fell to zero last week due to two main reasons. Junk bond issuers stayed away from the primary market due to fears of default risk.

    By Lynn Noah
  • uploads///Junk Bond Yields in  and
    Company & Industry Overviews

    Clear Channel International: The Only Junk Bond Issuer in the Week Ending December 11

    An indirect and wholly owned subsidiary of Clear Channel Outdoor Holdings, Clear Channel International issued $225 million in dollar-denominated junk bonds.

    By Lynn Noah
  • uploads///md pm
    Earnings Report

    MEDNAX Revenue and Income Rose After 3Q15 Results

    MEDNAX’s YTD price movement was a mix of rises and falls in 2015. After the earnings report, MEDNAX fell 3.4% to close at $71.3 per share as of October 29, 2015.

    By Gabriel Kane
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.